An insert for a luer-type catheter connection includes a fluid pathway connecting a female end and a male end. The male end is configured for slidable insertion into a female luer fitting of a catheter, and the female end is configured to receive a male luer nozzle of a fluid delivery device. The insert also includes a threaded collar having internal threading faced for coupling with the female luer fitting and external threading faced for coupling with a locking collar on the fluid delivery device. A cartridge located in the fluid pathway is configured to hold a patency agent and further to release the patency agent into the catheter when fluid is passed through the cartridge.

Systems, devices, and methods for delivering therapeutic particles are disclosed. In one variation, a device for delivering particles includes a gas supply configured for supplying gas under pressure, a particle cassette comprising the particles, a cassette housing, and a cassette membrane. The cassette housing can comprise an Ethylene Vinyl Acetate (EVA) copolymer of 18% to 28% by weight of Vinyl Acetate (VA). The device can also include a safety interlock to prevent or minimize the risk that the device will be unintentionally activated. The device can also have a silencer.

Systems, devices, and methods for delivering therapeutic particles are disclosed. In one variation, a device for delivering particles includes a gas supply configured for supplying gas under pressure, a particle cassette comprising the particles, a cassette housing, and a cassette membrane. The cassette housing can comprise an Ethylene Vinyl Acetate (EVA) copolymer of 18% to 28% by weight of Vinyl Acetate (VA). The device can also include a safety interlock to prevent or minimize the risk that the device will be unintentionally activated. The device can also have a silencer.

Provided is an applicator for the dispensing of a powder such as a pharmaceutical powder, on a target location. Also, provided are methods of applying a powder on a surface using the applicator.

The present disclosure relates to a needleless syringe and method for delivering therapeutic particles. A source of therapeutic particles is located between a gas source and a cannon having a side opening. Gas released from the gas source causes a propagation of the therapeutic particles through the cannon. The side opening causes a reduction of a pressure of the gas in the cannon.

An apparatus and method for depositing a particulate containing composition onto mammalian skin such that when the particles contact the mammalian skin they have a momentum defined by vr, which is within the range of about 0.1 kg/msvrabout 12.0 kg/ms. The particles can be in the range of from about 10 nanometers to about 10 micrometers, in size. And the particles may be selected from the group consisting of titanium dioxide, zinc oxide, iron oxide, polyethylene, polypropylene, polyethylene terephthalate, polycarbonate, polyvinyl chloride, glass, silica and mixtures thereof. The particles are imbedded below the first layer of dead skin cells in the stratum corneum but they do not pass all the way through the stratum corneum into the living cells of the epidermis or dermis layers of the skin.

This invention discloses methods and composition to form biodegradable polymer implant arrays in the live tissue. Artificial cavities are created in the live tissue by using laser ablation, oscillating needle, microneedle array and other methods. The cavities are then filled with biodegradable polymer solution. The solvent in the polymer solution is dissipated in the tissue to form a biodegradable polymer implant in artificial cavities. The cavities and implants formed are arranged to form of an array of implants. The biodegradable polymer in the cavity can also be loaded with drug to form biodegradable drug delivery array in the live tissue.

Methods and compositions are for preparing microimplant arrays for sustained drug delivery or live cell based therapy. The array in array (AIA) device enables formation of microimplant arrays without having tissue piercing elements to the microimplant. The methods and compositions are for solid state delivery of drugs, especially biologics drugs without forming a drug solution prior to injection. New methods and compositions are for preparing in situ arrays for sustained drug delivery or live cell based therapy. Tissue surface is first treated with laser drilling, microneedle array, mechanical drilling or other methods to create artificial micro-porosity of various sizes, shapes and patterns. The artificial pores created are then infused with sustained drug delivery compositions or live cell suspensions. The compositions are converted into solid or semisolid state by physical or chemical reaction/s to entrap drug or live cells. The entrapped drug or live cells provide local or systemic therapeutic benefit.

A method of forming a gel implant in tissue can include: providing an injectable composition configured for thermoreversible gel formation at about 37 C.; injecting the injectable composition into the tissue at the rate of about 10-12000 injections per minute; and forming a thermoreversible gel at about 37 C. from the injected injectable composition so as to form the gel implant. The injecting can be at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection. The injecting can form an implant with area greater than or equal to 5 mm.sup.2. The injecting can be at a depth of 10 microns to 5 mm. The injectable composition can include a visualization agent, drug or other agent.

A method of forming an implant in the tissue can include: providing an injectable composition having a neat liquid carrier, wherein the neat liquid carrier is substantially liquid at room temperature and/or about body temperature; and injecting the neat liquid solution into the tissue at the rate of 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection. The neat liquid carrier can be polymeric or non-polymeric. The neat liquid carrier can be biodegradable. The neat liquid carrier can include a viscosity-modifying agent. The injecting can form an implant with area greater than or equal to 5 mm.sup.2. The neat liquid carrier can be injected at a depth of 10 microns to 5 mm. The neat liquid solution can include a drug or other agent.